Insmed (NASDAQ:INSM) Insider Orlov Nicole Schaeffer Sells 87,290 Shares

Insmed, Inc. (NASDAQ:INSM) insider Orlov Nicole Schaeffer sold 87,290 shares of Insmed stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the transaction, the insider directly owned 41,754 shares in the company, valued at $7,315,300.80. This represents a 67.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Insmed Trading Down 0.1%

INSM traded down $0.13 on Tuesday, reaching $175.07. 1,850,202 shares of the company’s stock were exchanged, compared to its average volume of 1,981,131. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The company’s 50 day moving average is $190.42 and its 200-day moving average is $150.55. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The company has a market cap of $37.34 billion, a price-to-earnings ratio of -28.28 and a beta of 1.08.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same period last year, the firm earned ($1.27) earnings per share. The company’s quarterly revenue was up 52.4% on a year-over-year basis. Equities analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Mizuho set a $212.00 target price on Insmed in a research report on Thursday, December 18th. Redburn Partners set a $263.00 price target on Insmed in a research report on Thursday, December 4th. Citigroup restated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Wedbush set a $203.00 price objective on shares of Insmed in a research report on Thursday, December 18th. Finally, Leerink Partners reissued an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $205.05.

Hedge Funds Weigh In On Insmed

A number of institutional investors have recently made changes to their positions in the business. Darwin Global Management Ltd. boosted its stake in shares of Insmed by 5.8% during the 3rd quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after buying an additional 1,112,824 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Insmed by 13.0% in the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after buying an additional 2,291,328 shares during the last quarter. Capital International Investors raised its holdings in Insmed by 1.0% in the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after acquiring an additional 74,994 shares in the last quarter. Artisan Partners Limited Partnership boosted its stake in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares during the last quarter. Finally, Duquesne Family Office LLC grew its holdings in Insmed by 3.0% during the 3rd quarter. Duquesne Family Office LLC now owns 2,423,435 shares of the biopharmaceutical company’s stock worth $348,999,000 after acquiring an additional 70,000 shares in the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.